Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More